Entegris (ENTG) Q2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2025 earnings summary
17 Dec, 2025Executive summary
Q2 2025 net sales were $792.4M, down 2.5–3% year-over-year but up 2–2.5% sequentially, exceeding guidance, driven by demand for CMP consumables, selective etch, and deposition materials.
GAAP net income was $52.8M (6.7% margin), down 22% year-over-year; adjusted net income was $100.6M, down 6.1%.
Adjusted EBITDA was $216.7M (27.3% margin), down 4.2% year-over-year.
Segment realignment in late 2024 resulted in two segments: Materials Solutions (MS) and Advanced Purity Solutions (APS).
Leadership transition: David Reeder to become CEO in August 2025; Bertrand Loy to serve as Executive Chair.
Financial highlights
Q2 2025 gross margin was 44.4% GAAP and 44.6% non-GAAP, down from 46.2% a year ago.
Adjusted EBITDA margin was 27.3% of revenue.
GAAP diluted EPS was $0.35; non-GAAP EPS was $0.66, both within guidance.
Free cash flow for Q2 was $47M; for the first half, $79M with a margin of 5%.
Cash and cash equivalents at quarter-end: $376.8M; long-term debt: $3,987.8M.
Outlook and guidance
Q3 2025 sales expected between $780M and $820M.
Q3 2025 GAAP net income guidance: $65M–$76M; GAAP EPS: $0.43–$0.50.
Q3 2025 non-GAAP net income: $104M–$115M; non-GAAP EPS: $0.68–$0.75.
Adjusted EBITDA margin for Q3 projected at ~27.5%.
Free cash flow margin targeted in the low double digits for 2025; second half expected to be stronger.
Latest events from Entegris
- Annual meeting to vote on directors, compensation, auditor, and key shareholder rights changes.ENTG
Proxy filing23 Mar 2026 - Proxy covers leadership transition, governance reforms, and performance-based compensation changes.ENTG
Proxy filing23 Mar 2026 - Strategic growth, governance reforms, and enhanced ESG drive long-term value creation.ENTG
Proxy Filing6 Mar 2026 - Q4 2025 delivered strong sales and margins, with robust 2026 guidance and ongoing deleveraging.ENTG
Q4 202510 Feb 2026 - Q2 sales rose sequentially with strong margins; Q3 guidance and investments support further growth.ENTG
Q2 20242 Feb 2026 - Adjusted sales up 7% year-over-year; Q4 outlook signals margin strength and cost savings.ENTG
Q3 202417 Jan 2026 - Q4 2024 delivered double-digit adjusted sales growth and margin expansion, beating guidance.ENTG
Q4 20248 Jan 2026 - Strong 2024 growth, robust governance, and key votes on directors, pay, auditor, and voting rights.ENTG
Proxy Filing1 Dec 2025 - Q1 2025 net sales rose 5% adjusted, with margin gains and tariff risks impacting outlook.ENTG
Q1 202517 Nov 2025